Justin cofounded and served as CTO of Serotiny, a Bay Area gene and cell therapy discovery company, which Johnson & Johnson acquired in early 2024. Currently, he runs the Serotiny platform at J&J within Therapeutics Discovery, Cell and Genetic Medicines. Justin earned his PhD from University of California, San Francisco in Zev Gartner’s lab studying the biophysics of the Notch receptor.  He cofounded Serotiny to apply scalable technologies to gene and cell therapy discovery. Serotiny couples its proprietary software to high-throughput assays in order scale discovery via data-driven engineering of therapeutic multi-domain proteins.